
|Articles|March 1, 2005
March FDA Pipeline
New approvals and actions in brief
Advertisement
The meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) was approved for protection against meningococcal disease in adolescents and adults aged 11 to 55 years.
FDA approved mometasone (Nasonex, Schering-Plough) for the treatment of nasal polyps in patients aged 18 years and older.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
UC Davis develops new drug for bladder cancer patients
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
5



















































